Preferred Label : Anti-LILRB2 Monoclonal Antibody IO-108;
NCIt synonyms : Anti-ILT4 Monoclonal Antibody IO-108;
NCIt definition : A monoclonal antibody directed against the inhibitory immune checkpoint receptor immunoglobulin-like
transcript 4 (LILRB2; ILT4; leukocyte immunoglobulin-like receptor subfamily B member
2; lymphocyte immunoglobulin-like receptor 2; LIR2; monocyte/macrophage immunoglobulin-like
receptor 10; MIR-10; CD85d), with potential immunomodulating and antineoplastic activities.
Upon administration, anti- LILRB2 monoclonal antibody IO-108 targets and binds to
LILRB2. This prevents the binding of LILRB2 ligands to their receptor and prevents
LILRB2-mediated signaling. This abrogates the immunosuppressive activities of LILRB2
in the tumor microenvironment (TME), activates the expression of pro-inflammatory
cytokines, including GM-CSF and tumor necrosis factor alpha (TNFalpha), and enhances
a cytotoxic T-lymphocyte (CTL)-mediated anti-tumor immune response. LILRB2, plays
a key role in tumor immune evasion. LILRB2, a transmembrane protein and inhibitory
member of the immunoglobulin-like transcript (ILT) family of proteins, is expressed
primarily by myeloid cells, including monocytes, macrophages, dendritic cells (DCs)
and granulocytes, and in certain tumors.;
Molecule name : IO-108; IO 108;
NCI Metathesaurus CUI : CL1778341;
Origin ID : C185720;
UMLS CUI : C5667022;
Semantic type(s)
- chemical_or_drug_has_mechanism_of_action
- concept_is_in_subset
- has_target
